Simultaneous Pancreas-Kidney Transplantation Vs. Deceased Donor Kidney Transplantation in Patients With Diabetes Mellitus – An Ongoing Controversy

Due to the infeasibility of a definitive RCT, the authors employed a propensity-weighted analysis. Undoubtedly, this is a sophisticated statistical method designed to simulate the balance of an RCT by adjusting for confounding variables. However, propensity-weighted analysis should only be performed if all relevant factors are available.Hence, the central question is: are the SPK and DDKTA groups in this study truly comparable? As evidenced in Table 1 of this article, the two groups differ significantly across all included baseline characteristics. This imbalance raises concerns about residual confounding and the validity of direct outcome comparisons, even after sophisticated statistical adjustment.The majority of SPK recipients had type 1 diabetes and met stringent listing criteria for pancreas transplantation. In contrast, DDKTA recipients either did not qualify, were declined, or opted out of a simultaneous pancreas transplant. For this reason alone, the two groups represent fundamentally different populations. The significant disparities in donor and recipient characteristics, as well as the unweighted survival outcomes, further underscore this deficiency. Therefore, applying weighted propensity scoring to estimate the probability of receiving an SPK among DDKTA recipients introduces bias, as the counterfactual scenario is not clinically feasible for most candidates. This methodological shortfall may cause misrepresentation of this study's true comparative effectiveness of SPK vs. DDKTA and will lead to wrong conclusions. [2] The study's overall comparative analysis between SPK and DDKTA recipients is challenged by significant cohort imbalances. There are fewer SPK recipients, and they have predominantly type 1 diabetes, whereas DDKTA recipients are more numerous and more often have type 2 diabetes. This disparity introduces inherent confounding, as the diabetes type is closely linked to disease progression, secondary complications, comorbidity profiles, and transplant eligibility. Moreover, several potentially influential patient characteristics were not accounted for in the authors' analysis, including age at disease onset, duration of diabetes, severity of disease and the severity of secondary complications, regional variations in treatment practices as well as transplant center volume. Almost all transplant centers in the United States transplant kidneys but not all centers transplant pancreata. These variables may have influenced both treatment selection and outcomes, further complicating interpretation of the study's results using incomplete registry data.Statistical adjustments cannot fully mitigate these confounders, especially when donor quality and transplant criteria vary across groups. As the authors showed, a more robust approach with stratified analyses within homogenous subgroups-such as limiting comparisons to patients with type 1 diabetes to reduce heterogeneity and enhance interpretability --revealed a lower mortality rate for SPK recipients in this study. This result was confirmed by previous studies which evaluated highly selective cohorts specifically for patients stratified either for type 1 or type 2 diabetes. The reason for these stratifications was to assess the differences in those groups and minimize the selection bias. [3] An SPK transplant is clearly a more difficult procedure than a DDKTA since two organs are transplanted. This naturally carries a higher risk of surgical morbidity and graft rejection.